Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

He, Xiaoli; Li, Jun; Xiao, Li; Zhao, Mengnan; Su, Tingting; Liu, Tiejian; Han, Guowei; Wang, Yue

doi:10.1186/s12885-020-06854-w

Cited by 5 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study [ 23 ] of 52 patients with advanced CC who received the cisplatin-paclitaxel-BEV triplet reported a median OS of 15.3 months and a median PFS of 9.8 months. Recently, a retrospective observational study [ 24 ] involving 264 Chinese women with advanced CC who underwent cisplatin-paclitaxel-BEV triplet or cisplatin-paclitaxel chemotherapy alone showed that the cisplatin-paclitaxel-BEV triplet is associated with improved survival compared to cisplatin-paclitaxel chemotherapy alone (median OS: 540 days [95% CI, 483–597] for cisplatin-paclitaxel-BEV triplet vs. 357 days [95% CI, 264–450)] for cisplatin-paclitaxel chemotherapy alone; HR 1.21, 95% CI, 1.14–1.73; p = 0.002). A phase 3 trial (GOG 240) [ 1 ] showed that the cisplatin-paclitaxel-BEV triplet yields more significant improvement in survival than cisplatin-paclitaxel chemotherapy alone.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Chu

Liu

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background The aim of this study was to assess the survival outcomes of cisplatin-paclitaxel chemotherapy plus bevacizumab (CPB) versus cisplatin-paclitaxel chemotherapy alone (CPA) in postmenopausal women with previously untreated advanced cervical cancer (CC). Methods Consecutive postmenopausal women who experienced CPB or CPA were identified retrospectively from our medical centre during 2015–2019. Follow-up visits occurred 1 and 3 months after starting CPB or CPA. Afterwards, this assessment was conducted every 3 months for 1 year and then yearly thereafter. The primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints were the frequency and severity of adverse events (AEs). Results Two hundred forty-six postmenopausal women were included (CPB, n = 124; CPA, n = 122). The median follow-up for the entire cohort was 24 months (range, 2–32). At the final follow-up, a significant difference was detected in terms of median OS (16.4 months [95% CI, 15.3–17.1] for CPB vs. 12.3 months [95% CI, 10.2–13.5] for CPA; hazard ratio (HR) 0.69, 95% CI, 0.49–0.99; p = 0.001), and the median PFS was longer in the CPB group than in the CPA group (9.2 months [95% CI, 8.3–10.7] vs. 7.9 months (95% CI, 6.1–8.6) (HR 0.62, 95% CI, 0.47–0.82; p < 0.001). There were significant differences in the number of AEs between the groups (hypertension grade ≥ 2 [p < 0.001], neutropenia grade ≥ 4 [p < 0.001], and thrombosis/embolism grade ≥ 3 [p = 0.030]). Conclusions Among postmenopausal women with previously untreated advanced CC, those who received CPB experienced superior survival benefits compared to those who received CPA. The safety profile for CPB was controllable despite the long duration of CPB use.

show abstract

Section: Discussionmentioning

confidence: 99%

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Chu

Liu

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Previously, two large studies have retrospectively evaluated the efficacy and safety of standard BEV dose of 15 mg/kg combined with CBC in cervical cancer. 17,20 In a recent study employing CBC + BEV (15 mg/kg) to treat Chinese women with cervical cancer, OS was not reached at 1 year, and it reached 45% at 2 years, 20 which is lower than the OS of our CBC + BEV (7.5 mg/kg), 85.7% and 66.6%, respectively. Furthermore, contrary to our finding, thrombosis/embolism and neutropenia were reported as significant AEs.…”

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

“…11 Numerous retrospective studies have also evaluated the efficacy and safety of the standard dose of BEV in patients with advanced cervical cancer and reported varying survival outcomes and AEs. [17][18][19][20][21][22] Besides, it is well-known that most patients with advanced cervical cancer have a low social-economic status, and many of these patients cannot afford the high cost of BEV without prior additional health care coverage. A previous cost-effectiveness study has shown that the cost of treatment decreased from $49 831 to $26 472 when the BEV dosage was reduced from 15 to 7.5 mg/kg.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer

Liu

Kung

Lin

et al. 2021

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Cisplatin-based chemotherapy (CBC) is highly efficacious for advanced cervical cancer; its efficacy can be enhanced by combining with 15 mg/kg (standard dose) bevacizumab (BEV). However, this standard dose is associated with various adverse events (AEs). Therefore, in this retrospective study, we analyzed the survival outcomes and AEs in patients with advanced or recurrent cervical cancer treated with CBC in combination with BEV 7.5 mg/kg. Methods: Registered patient data were retrieved between October 2014 and September 2019, and 64 patients with advanced or recurrent cervical cancer treated with CBC + BEV (n = 21) or CBC alone (n = 43) were analyzed. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the secondary endpoints were the frequency and severity of AEs. The Cox proportional-hazards model was applied to explore prognostic factors associated with PFS and OS. Results: The 1-, 2-, and 3-year PFS rates (95% CI) were 36.24% (22.0-50.5), 20.7% (9.8-34.2), and 17.7% (7.7-31.1) for the CBC group; and 71.4% (47.1-86.0), 51.0% (27.9-70.1), and 51.0% (27.9-70.1) for the CBC + BEV group, respectively. The 1-, 2-, and 3-year OS rates were 62.6% (46.4-75.18), 32.4% (18.8-46.9), and 23.2% (11.2-37.6) for the CBC group; and 85.7% (61.9-95.1), 66.6% (42.5-82.5), and 55.5% (27.1-76.7) for the CBC + BEV group, respectively. The CBC + BEV group presented higher PFS and OS rates, p = 0.003 and p = 0.005, respectively. Proteinuria (6 vs 9, p = 0.025) and hypertension (0 vs 10, p < 0.001) were less common, but anemia was more common in the CBC group (35 vs 11, p = 0.021). Conclusion: Overall, CBC + BEV significantly improved the PFS and OS compared with CBC alone. CBC + BEV also prevents severe AEs and hence is an efficacious and safe therapeutic option.

show abstract

“…Recently, three studies were conducted in three different centers in China on a larger number of patients and with a control group. Two of these studies had similar results and toxicity profiles to the registrational trial [24,25]. Meanwhile, the primary outcome of the third study was to assess the toxicity rate, and despite the benefit of bevacizumab, the combined treatment was not well tolerated due to higher grades of neutropenia, gastrointestinal fistula, and hypertension [26].…”

Section: Discussionmentioning

confidence: 98%

Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients

Čerina

Matković

Katić

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. Although today it is almost preventable, cervical cancer still represents a significant cancer burden, especially in some developing parts of the world. Since the introduction of bevacizumab in the first-line treatment of metastatic disease, improvements of the outcomes were noted. However, results from randomized controlled trials are often hard to recreate in the real-world setting. Objective. To assess the real-world efficacy and safety of bevacizumab as a first-line treatment of advanced cervical cancer. Methods. We conducted a retrospective cohort study on the total population of Croatian patients diagnosed with metastatic cervical cancer from 2016 to 2019 who were treated with bevacizumab in combination with cisplatin and paclitaxel (TCB) in the first line. The comparison group was the consecutive sample of patients treated with chemotherapy alone. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, incidence of adverse events, and the proportion of treatment discontinuation. Results. We enrolled 67 patients treated with TCB and a control group of 62 patients treated with chemotherapy alone. The TCB cohort had significantly longer unadjusted OS with a median of 27.0 (95% CI 18.5; not calculable) months, compared to 15.5 (10.7; 30.1) months in the chemotherapy-alone cohort. Adjusted OS was not significantly different. PFS was significantly longer for the TCB cohort, with a median of 10.6 (95% CI 8.5; 15.4) months, than for the chemotherapy-alone cohort, with a median of 5.4 (95% CI 3.9; 9.1) months, even after adjustment for baseline covariates (HRadjusted = 0.60; 95% CI 0.39; 0.94; p = 0.027 ; false discovery rate <5%). Conclusions. In a real-world setting, TCB as a first-line treatment of metastatic cervical cancer was associated with longer PFS, better objective disease control rate, and acceptable toxicity profile in comparison to chemotherapy alone. These results may indicate its utility and potential applicability in other parts of the developing world.

show abstract

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

Cited by 5 publications

References 28 publications

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer

Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients

Contact Info

Product

Resources

About